Incidence and impact on clinical outcome of infections with piperacillin/tazobactam resistant Escherichia coli in ICU: A retrospective study - Université d'Angers Accéder directement au contenu
Article Dans Une Revue BMC Infectious Diseases Année : 2008

Incidence and impact on clinical outcome of infections with piperacillin/tazobactam resistant Escherichia coli in ICU: A retrospective study

Résumé

Escherichia coli infections are frequent in ICU patients. The increased resistance to fluoroquinolones and amoxicillin/clavulanate of this pathogen mandates the prescription of broad-spectrum antibiotics such as piperacillin/tazobactam (PIP-TAZ) or third generation cephalosporins (3GC).

Dates et versions

hal-03134627 , version 1 (08-02-2021)

Identifiants

Citer

Agnès Meybeck, Jean-Damien Ricard, Guilène Barnaud, Matthieu Eveillard, Guillaume Chevrel, et al.. Incidence and impact on clinical outcome of infections with piperacillin/tazobactam resistant Escherichia coli in ICU: A retrospective study. BMC Infectious Diseases, 2008, 8 (1), Non spécifié. ⟨10.1186/1471-2334-8-67⟩. ⟨hal-03134627⟩
17 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More